Cargando…

Impact of lipid-lowering therapy on the prevalence of dyslipidaemia in patients at high-risk of cardiovascular events in UK primary care – a retrospective database study

AIMS: To estimate the prevalence of dyslipidaemias in high-risk patients new to lipid-modifying therapy (LMT), and establish the extent to which these lipid abnormalities are addressed by treatment in UK clinical practice. METHODS: The PRIMULA study was a retrospective analysis, conducted using the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jameson, K, Amber, V, D'Oca, K, Mills, D, Giles, A, Ambegaonkar, B
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BlackWell Publishing Ltd 2013
Materias:	Cardiovascular
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4232237/ https://www.ncbi.nlm.nih.gov/pubmed/23944233 http://dx.doi.org/10.1111/ijcp.12238

Ejemplares similares

Prevalence of persistent lipid abnormalities in statin-treated patients: Belgian results of the Dyslipidaemia International Study (DYSIS)
por: Devroey, D, et al.
Publicado: (2014)

Prevalence of dyslipidaemia in statin-treated patients in South Africa: results of the DYSlipidaemia International Study (DYSIS)
por: Raal, Frederick J, et al.
Publicado: (2013)

Lipid‐lowering treatment patterns in patients with new cardiovascular events – estimates from population‐based register data in Sweden
por: Hallberg, S., et al.
Publicado: (2016)

New Perspectives on Atherogenic Dyslipidaemia and Cardiovascular Disease
por: Lorenzatti, Alberto J, et al.
Publicado: (2020)

Association of homocysteinaemia with hyperglycaemia, dyslipidaemia, hypertension and obesity
por: Moraba, Mpho, et al.
Publicado: (2013)

Longitudinal evaluation of treatment patterns, risk factors and outcomes in patients with cardiovascular disease treated with lipid-lowering therapy in the UK
por: Danese, Mark, et al.
Publicado: (2022)

Potential curing and beneficial effects of Ooitabi (Ficus pumila L.) on hypertension and dyslipidaemia in Okinawa
por: Suzuki, K., et al.
Publicado: (2020)

Management of lipid-lowering therapy in patients with cardiovascular events in the UK: a retrospective cohort study
por: Danese, Mark D, et al.
Publicado: (2017)

Prevalence and incidence of dyslipidaemia among adults in Africa: a systematic review and meta-analysis protocol
por: Noubiap, Jean Jacques N, et al.
Publicado: (2015)

The Role of Nutraceuticals in the Optimization of Lipid-Lowering Therapy in High-Risk Patients with Dyslipidaemia
por: Penson, Peter E., et al.
Publicado: (2020)

Interaction between dyslipidaemia, oxidative stress and inflammatory response in patients with angiographically proven coronary artery disease
por: Tayal, D, et al.
Publicado: (2012)

Atherosclerotic Cardiovascular Disease Risk and Lipid-Lowering Therapy Requirement in China
por: Bi, Lei, et al.
Publicado: (2022)

Ezetimibe, cardiovascular risk and atherogenic dyslipidaemia
por: Rizzo, Manfredi, et al.
Publicado: (2011)

Red meat consumption and risk for dyslipidaemia and inflammation: A systematic review and meta-analysis
por: Sun, Le, et al.
Publicado: (2022)

Higher docosahexaenoic acid levels lower the protective impact of eicosapentaenoic acid on long-term major cardiovascular events
por: Le, Viet T., et al.
Publicado: (2023)

Associations between body fat distribution, insulin resistance and dyslipidaemia in black and white South African women
por: Keswell, Dheshnie, et al.
Publicado: (2016)

Risk of major adverse cardiovascular events associated with elevated low-density lipoprotein cholesterol in a population with atherosclerotic cardiovascular disease with and without type 2 diabetes: a UK database analysis using the Clinical Practice Research Datalink
por: Morgan, Christopher Ll, et al.
Publicado: (2023)

Retrospective examination of lipid-lowering treatment patterns in a real-world high-risk cohort in the UK in 2014: comparison with the National Institute for Health and Care Excellence (NICE) 2014 lipid modification guidelines
por: Steen, Dylan L, et al.
Publicado: (2017)

Effectiveness of lipid-lowering therapy on mortality and major adverse cardiovascular event outcomes in patients undergoing percutaneous coronary intervention: a network meta-analysis of randomised controlled trials
por: Deng, Chang-Jiang, et al.
Publicado: (2023)

Risk of cardiovascular event and mortality in relation to refill and guideline adherence to lipid-lowering medications among patients with type 2 diabetes mellitus in Sweden
por: Karlsson, Sofia Axia, et al.
Publicado: (2019)

Design and rationale of the ODYSSEY DM-DYSLIPIDEMIA trial: lipid-lowering efficacy and safety of alirocumab in individuals with type 2 diabetes and mixed dyslipidaemia at high cardiovascular risk
por: Müller-Wieland, Dirk, et al.
Publicado: (2017)

Effects of intensive lipid lowering compared with moderate-intensity lipid lowering on coronary atherosclerotic plaque phenotype and major adverse cardiovascular events in adults with low to intermediate 10-year ASCVD risk (ILLUMINATION study): protocol for a multicentre, open-label, blinded-endpoint, randomised controlled trial
por: Zheng, Jianan, et al.
Publicado: (2023)

Trends in Prevalence of Dyslipidaemias and the Risk of Mortality in Lithuanian Urban Population Aged 45–64 in Relation to the Presence of the Dyslipidaemias and the Other Cardiovascular Risk Factors
por: Luksiene, Dalia, et al.
Publicado: (2014)

Inflammation and dyslipidaemia: a possible interplay between established risk factors in North Indian males with coronary artery disease
por: Goswami, Binita, et al.
Publicado: (2010)

Provincial heterogeneity in the management of care cascade for hypertension, diabetes, and dyslipidaemia in China: Analysis of nationally representative population-based survey
por: Zhao, Yang, et al.
Publicado: (2022)

UK stroke incidence, mortality and cardiovascular risk management 1999–2008: time-trend analysis from the General Practice Research Database
por: Lee, Sally, et al.
Publicado: (2011)

Diabetic dyslipidaemia
por: C. Thambiah, Subashini, et al.
Publicado: (2021)

Cardiovascular Toxicity of Carfilzomib: The Real-World Evidence Based on the Adverse Event Reporting System Database of the FDA, the United States
por: Zhai, Yinghong, et al.
Publicado: (2021)

Estimating the economic burden of cardiovascular events in patients receiving lipid-modifying therapy in the UK
por: Danese, Mark D, et al.
Publicado: (2016)

The changes of immunoglobulin G N-glycosylation in blood lipids and dyslipidaemia
por: Liu, Di, et al.
Publicado: (2018)

Lipid-lowering treatment patterns among patients with type 2 diabetes mellitus with high cardiovascular disease risk
por: Quek, Ruben G W, et al.
Publicado: (2015)

Novel Insight Into Long-Term Risk of Major Adverse Cardiovascular and Cerebrovascular Events Following Lower Extremity Arteriosclerosis Obliterans
por: Sun, Ji, et al.
Publicado: (2022)

Glucose-Lowering and the Risk of Cardiovascular Events With Antidiabetic Therapies: A Systematic Review and Additive-Effects Network Meta-Analysis
por: de Carvalho, Luiz Sergio Fernandes, et al.
Publicado: (2022)

Correlation of triglyceride–glucose index and dyslipidaemia with premature coronary heart diseases and multivessel disease: a cross-sectional study in Tianjin, China
por: Wei, Ao, et al.
Publicado: (2022)

Dyslipidaemia—Genotype Interactions with Nutrient Intake and Cerebro-Cardiovascular Disease
por: Lee, Sung-Bum, et al.
Publicado: (2022)

High residual cardiovascular risk after lipid-lowering: prime time for Predictive, Preventive, Personalized, Participatory, and Psycho-cognitive medicine
por: Reijnders, E., et al.
Publicado: (2023)

Dyslipidaemia in Rheumatological Autoimmune Diseases
por: Toms, Tracey E, et al.
Publicado: (2011)

Fixed Combination for the Treatment of Dyslipidaemia
por: Ferri, Nicola, et al.
Publicado: (2023)

Secondary Prevention Using Cholesterol-Lowering Medications in Patients with Prior Atherosclerotic Cardiovascular Disease Events: A Retrospective Cohort Analysis
por: Han, Xue, et al.
Publicado: (2022)

FRI085 Lipid Lowering Therapy Deficits In Secondary Cardiovascular Prevention In A Large Cohort From Eight Busy Clinics In Greece Over 12 Years
por: Paparodis, Rodis D, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_cv0926c0mann3pka3ljmhpp72o